HER2 Testing in Gynecologic Cancers and Implications for Treatment
Activity Description:
This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in HER2-directed therapies in gynecologic cancers and of treatment options based on HER2 results. A particular focus of this activity is the DESTINY-PanTumor02 study and the latest evidence regarding HER2 testing, scoring and reporting in gynecologic cancers. The microlearning design of this activity allows for a brief and focused exploration of this topic.
Course topics include:
DESTINY-PanTumor02 and other trials evaluating HER2-directed therapies in gynecologic cancers
HER2 testing and scoring in endometrial, cervical, ovarian cancers
Specimen handling, scoring, reporting
Treatment implications based on HER2 results
Faculty/Authors
Jennifer MacDonald, PharmD, BCOP Clinical Pharmacy Specialist, Gynecologic Oncology Hollings Cancer Center, Medical University of South Carolina Charleston, South Carolina
Sadia Sayeed MD Assistant Professor of Pathology, Director of Cytopathology, Department of Pathology Virginia Commonwealth University Health Richmond, Virginia
Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement CME/CMLE Credit: 0.25Estimated Completion Time: 0.25 hourFormat: Online educational activity
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Credit Designation Statement
The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of .25 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must have participated in the course. CME certificates will be provided online
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Instructions
To claim CME/CMLE credit for the exercise, do the following:
Upon completion of this activity, you will be able to:
Review the DESTINY-PanTumor02 and other trials evaluating HER2-directed therapies in gynecologic cancers
Describe methods of HER2 testing and scoring in endometrial, cervical, ovarian cancers
Discuss practical considerations around specimen handling, scoring, reporting
Understand treatment implications for patients based on HER2 results